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ABSTRACT 
An abstract of the thesis of Shanli Ye for the Master of Science in Biology presented 
November 29, 1995. 
Title: DNA Sequences Involved in The Regulation of Human c-myc Gene Expression by 
Herpes Simplex Virus Type 1 (HSV-1). 
The human c-myc gene is a cellular proto-oncogene composed of three exons and two 
introns. Transcription of c-myc is controlled by two promoters, Pl and P2. The activity 
of these promoters is regulated by many factors, such as cellular transcription factors E2F, 
YYl, and HSV-1 immediate-early proteins, ICPO, ICP4. 
Many regulatory elements located both upstream of and between P 1 and P2 have been 
identified, and some of these are required for optimum expression of c-myc. In this thesis 
research, a region downstream from P2 in the c-myc exon 1 was identified by its response 
to transactivation by HSV-1 immediate-early proteins, ICPO and ICP4. The purpose of this 
research was to examine this region for regulatory sites that respond to HSV-1 infection. 
I hypothesized that after HSV-1 infection, ICPO and ICP4 activate c-myc expression, in 
part, through regulatory sequences present in exon 1. 
To test for this hypothesis, reporter plasmids containing (I) the c-myc promoter (from -
101 bp relative to Pl) and exon 1 coupled to the bacterial CAT gene were constructed. 
(ii) The c-myc exon sequences used were either intact (wild-type) or they were constructed 
with various deletions. The activities of these plasmids were examined in transient 
expression assays. To analyze protein binding, electrophoretic mobility shift assay (EMSA) 
. --·--- ----·--·-"" - .,, ____________________ _ 
and completion EMSAs were carried out. The results from these experiments lead to the 
following conclusions: (i) ICP4 and ICPO serve as activators, whereas ICP27 inhibits c-myc 
gene expression. (ii) The region from +332 to +513 within the c-myc exon 1 contains 
an important element required for transactivation of the c-myc gene by HSV-1 proteins. 
(iii) Cellular proteins, including factor YYl, bind to the region from +332 to +513 in the 
c-myc exon 1. 
Although the exact mechanism by which HSV-1 immediate-early proteins regulate c-
myc gene expression is still not clear, it gives rise to a possibility that this regulation is 
caused by turning on or activation of the cellular regulatory proteins by ICP4 and ICPO. 
The cellular proteins in turn activate the c-myc gene expression by interacting with the cis-
element downstream from P2. 
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GENERAL BACKGROUND 
1. PREVIOUS STUDIES ON c-MYC REGULATION 
The c-myc gene is the cellular homolog of the v-myc oncogene which was first detected as the 
transforming sequence of the avian myelocytomatosis virus (58). In humans, the c-myc gene was 
mapped to chromosome 8 (8q24) (5) and it is composed of three exons and two intrans. Exon 2 
and exon 3 contain the coding information for the c-myc protein, while exon l is an untranslated 
leader that is highly conserved between human and mouse (2) and entirely absent from v-myc (70). 
Within the exon 1, there are ~o promoters designated as Pl and P2 which are separated about 170 
base pairs (for human c-myc gene) (33). The products encoded by c-myc gene are two 
phosphoproteins that are initiated at independent translational sites (29). These phosphoproteins 
are expressed at a low constitutive level in growing cells and arc down-regulated in quiescent and 
differentiated cells (38). They are thought to function as transcriptional activators and they arc 
involved in the regulation of proliferation, mitogenesis, and differentiation ( 40). In addition there is 
evidence that they play a role in programmed cell death (apoptosis) (52) and in the cytotoxicity of 
TNF-a in tumor.cells (37). 
Early studies have already revealed that overexpression of c-myc (or deregulation of c-myc 
expression) is related to the . tumorigenesis of many kinds of human cancers such as Burkitt's 
lymphoma (BL), colon cancer (15), and breast cancer (16). In BL case, the c-myc gene is 
translocated into first intron of the immunoglobulin (lg) heavy chain gene located on the 
chromosome 14 [human, t(8,14)]. The immunoglobulin enhancer element located in the intron 
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causes the c-myc gene to be over-expressed. This suggested that deregulation of c-myc expression 
was important for multistage carcinogenesis. 
To understand how c-myc functions in these varied processes, it is important to understand what 
factors, both endogenous and exogenous, are involved in regulating the c-myc expression both in 
the normal cell cycle and in the tumor cells. We already know that c-myc expression is dependent 
on the presence of certain growth factors, e.g. platelet-derived growth factor (PDGF) (38), and on 
certain transcription regulatory factors such as E2F (14), YYI (Yin Yang 1) (57), Spl (10), etc. 
In 1983, Kathleen Kelly et al found that c-myc mRNA was strongly induced (10- to 40-fold) by 
mitogens (e.g. lipopolysaccharides or concanavalin A) in lymphocytes and by PDGF in fibroblasts 
(38). Later Nissim Hay et al demonstrated that the 2.3 kilobase pair (kbp) region upstream from 
the first transcription start site, P 1, contained both positive and negative regulatory elements which 
were involved in regulating c-myc expression by cellular factors (33). 
Other previous studies showed that the c-myc expression was regulated at the level of elongation 
of transcription (premature tennination of transcription occurs in the first exon of c-myc exon) ( l, 
14, 53). Bentley and Groudine demonstrated that when the HL60 cells (human promyelocytic 
leukemia cell line) differentiated into granulocytes, by means of treating the HL60 cells with 
retinoic acid, the c-myc mRNA level was reduced 10-fold (1). With the nuclear runoff assays, they 
showed that this reduction was detected in the transcription of c-myc exon 2 but not c-myc exon 1. 
This observation suggested that c-myc transcriptional down-regulation was at the level of 
transcriptional elongation rather than initiation, and this transcriptional elongation block occurred 
in the first exon of the c-myc gene ( 1). 
One of the important findings in the regulation of human c-myc regulation came from a report by 
Hiebert et al. They found that the adenovirus pre-early (or immediate-early) protein EIA was able 
to activate the endogenous c-myc gene. By using site-directed mutagenesis of the E2F site located 
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at about 60 bp upstream of the P2 in the c-myc exon 1, they found that the E 1 A transactivation 
was mediated by cellular protein E2F (34). This suggested that E2F might play an important role 
in activating the c-myc gene expression. 
Another important observation is the recent report published by DesJardins and Hay. They 
identified and characterized six potential regulatory sites called CT boxes (i.e. cytosine-thymidine 
boxes) in the c-myc promoter. Five are located at upstream of Pl and one (CT-Ii) is located 
between Pl and P2 (10). Using a series of deletion mutations along with transfcction and 
electrophoretic mobility shift assays (EMSA), they found that these CT elements were binding sites 
for Sp 1 and Sp I-related zinc-finger regulatory proteins. Sp 1 binding was found to be responsible 
for activating P2-initiated transcription and inhibiting PI-initiated transcription ( 10), and this 
promoter usage shift (shift the promoter usage from P 1 to P2) was observed in the normal 
individual. 
The early studies described above suggest that human c-myc gene expression is regulated at 
multiple stages and is regulated by multiple factors, including different cellular regulatory proteins, 
growth factors, viral proteins and certain mitogens. These factors may regulate c-myc gene 
expression by different mechanisms (e.g. by activating initiation of the c-myc transcription or 
blocking elongation of the c-myc mRNA) The activation by these factors may cause the 
overexpression of c-myc gene which can lead to multistage carcinogenesis. 
2. GENE REGULATION OF HSV-1 
In order to understand how herpes simplex virus type l (HSV-1) infection may be involved 
regulation of c-myc gene expression, it is necessary to introduce some general aspects of HSV-1 
replication. HSV-1 is a member of the viral family Herpesviridae and is composed of four basic 
structures: an envelope with viral glycoproteins, a tegument, a capsid, and a DNA-containing core. 
Analysis of the complete sequence of the HSV-1 genome has revealed that its genome has a total 
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size 15 2 kbp and contains at least 70 distinct genes ( 41). Based on the kinetics and characteristics 
of their expression, these genes can be divided into three main classes: immediate-early genes (IE, 
or a genes), early genes (E, or p genes), and late genes (L, or y genes). The expression of these 
genes is coordinately regulated and sequentially ordered in a cascade fashion: IE->E->L. The 
expression of late (or y) genes requires viral DNA replication. Based on expression time and the 
degree of requirement of the DNA replication , the y genes are divided into two subgroups, Yi (for 
example, the major capsid protein, YP5, gene) and Y2 (for example, the glycoprotein C, gC, gene). 
The y1 genes, also called py or leaky-late genes, are late genes start their expression before the viral 
DNA synthesis. However their full expression need the viral DNA synthesis. Thus their 
expression can still be detected (in a lower amount) in the presence of DNA synthesis inhibitors. 
On the other hand, y2 genes are expressed after viral DNA replication and they have a high 
stringency for viral DNA synthesis. In the presence of DNA synthesis inhibitors, the expression of 
y2 genes is almost totally blocked. The relationship between the late genes expression and viral 
genome replication is not clear. 
The IE class genes are defined as those which can be transcribed in the absence of de novo viral 
protein synthesis, and they code for five proteins (infected cell polypeptides) designated as ICPO, 
ICP4, ICP22, ICP27, and ICP47. Three of these immediate-early .proteins, ICP4, ICPO, and 
ICP27, are main regulatory proteins for the HSY-1 gene expression (7, 12, 19, 26, 51). ICP4 is a 
DNA sequence.,.specific binding protein (11. 20, 44) and a phosphoprotein essential for viral 
replication. However, the binding of ICP4 to its consensus binding sites may not be re9uired for its 
activation function (65). The ICP4 regulatory roles in the HSY genes expression have been 
revealed in early studies: (i) ICP4 is a major transactivator for HSY early and late gene expression; 
(ii) ICP4 represses its own expression and that of other a. genes expression. These ICP4 functions 
were demonstrated by the study of ICP4 temperature-sensitive (ts) mutants. Dixon and Schaffer 
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demonstrated that, at non-permissive temperature or in the temperature shift experiments, ICP4 ts 
mutants exhibited severe impairment in the expression of viral early (VP64) and late (VPlOO, 
VP154) genes and the overproduction of the a. genes, such as ICP4, ICP22, ICP27 (12). Later, 
similar results were derived from the studying the regulatory roles of ICP4 by using ICP4 mutants 
(ts mutants, deletion mutants, and nonsense mutants), assayed by transfection or cotransfcction 
experiments, or by detecting and comparing the different HSV mRNA between wild types ICP4 
and different kinds of mutated ICP4 (6, 7, 8). Recently, Gu et al showed that the ICP4 
autoregulatory function was related to the cellular protein Sp 1 (26). 
Another HSV-1 a. gene essential for viral replication is the ICP27 gene. By using temperature-
sensitive (ts) mutants, Sacks et al showed that the growth of ICP27 ts mutants was markedly 
impaired at non-permissive temperature, and the expression of three class HSV -1 genes were 
altered (overexpression some of a. genes and underexpression some of late genes) (59). These 
results indicated that ICP27 played an important regulatory function in HSV replication and it was 
required for the expression of HSV late genes. Later, the regulatory functions of ICP27 were 
revealed at both the transcriptional and post-transcriptional level (39, 55, 61). Further study on the 
post-transcriptional regulatory role of ICP27 revealed that ICP27 could affect mRNA processing 
(42, 43, 48, 59, 62), because its regulatory activity appeared to b~ promoter-independent and 
related to the mRNA processing signals present (62). In a system that used the TK (thymidine 
kinase) promot~r sequence fused to different reporter genes, lacZ and CAT, Sandri-Goldin and 
Mendoza found that the ICP27 activity was related to the reporter gene structure, but not the 
promoter. They found that pTK-CAT was repressed 12-fold when cotransfected with ICP27, but 
there was no effect on pTK- lacZ (62). In agreement with this observation, Hardwicke and Sandri-
Goldin demonstrated that when cells were infected with viral mutants defective in ICP27, the 
accumulated levels of at least three spliced host mRNAs were higher than those seen with wild-type 
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infected cells (30). This suggested that the host shut off function of ICP27 might be due to an 
effect on cellular mRNA splicing. 
In contrast to ICP4 and ICP27, ICPO was demonstrated to be required , but not essential, for 
viral growth. This was based on the observation that ICPO mutants of HSV-1 were viable in cell 
culture, albeit more sluggishly than the wild-type (60). It has been shown in transient expression 
experiments that ICPO is the only one of all HSV-1 inunediate-early proteins that was able to 
activate all three classes ofHSV-1 genes (15, 16, 22, 19, 54). The activation function ofICPO can 
be performed either by itself alone, e.g. in the case of activation of HSV-1 ribonucleotide reductase 
(RRl) gene (9), or in a synergistic manner with ICP4. However the activation function of ICPO 
seems to be paradox, since in ICP4 mutants (wild type ICPO) , the expression of HSV-1 early and 
late genes is not activated (6, 12). This paradox may be explained by the requirement of ICP4 for 
the nuclear localization of ICPO (72). In addition, ICPO has been·thought to play an important role 
in the HSV-1 latency (68). Besides the functions of the three HSV-1 inunediate-early proteins 
described above, these proteins are also involved in regulating the expression of certain cellular 
genes (4, 30, 62). 
3. PREVIOUS WORK ON ACTIVATION OF c-MYC EXPRESSION BY HSV-1 
In 1992, Shin Chen et al reported a cellular regulatory protein, leaky-late binding factor (LBF) 
was involved in the activation of HSV-1 major capsid protein VP5 promoter. By using DNA 
footprint and s~quence analysis, they found that the LBF target sequence, the leaky-late binding 
sequence (LBS}, was very similar to that of a recently described cellular protein, YYI. Using 
competition electrophoretic mobility shift assay, they revealed that LBF and YYl might be the 
same protein (4). Furthermore, using transient expression assays with HSV-1 superinfection or 
cotransfection of HSV-1 immediate-early proteins, they demonstrated that optimal transactivation 
of the VP5 promoter depended on an intact YYI binding site (4). Recently, Lisa Mills et al 
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confirmed that LBF is the same protein as YYl (47). These reports suggested that HSV-1 
immediate-early proteins could activate HSV-1 leaky-late genes, such as the VP5 and gD genes 
through cellular factor YYl. On the other hand, YYl has been shown to be an activator of c-myc 
gene expression (57). From sequence analysis of the c-myc gene, several potential YYl binding 
sites were detected. One is located at downstream from the second promoter in the first c-myc 
exon (another one is located around -240 bp). These observations led Dr. Millette to propose that 
HSV-1 infection might involved in activating c-myc expression. He and J. Paulson found: (i) The 
c-myc expression was activated by HSV-1 infection. ·(ii) HSV-1 treated with UV radiation failed · 
to transactivate c-myc expression ( 46). These results suggested that some products produced by 
HSV-1 had a positive effects on the c-myc gene. Using cotransfection of HSV-1 immediate-early 
proteins, they showed that this transactivation was due to the HSV-1 immediate-early proteins, 
ICP4 and ICPO. ICP4 appeared to be the major transactivator, since when cotransfected with 
ICP4 only, the wild type CAT activity increased about 100-fold as compared with those that were 
non-cotransfected (46). An important observation linking c-myc regulation with HSV-1 infection 
from Dr. Millette laboratory's is that this regulation may be associated with the cellular protein 
E2F. The maps of the plasmids construction for the wild type (+66 wt-Myc-CAT) and mutant 
type (+66 mtE2F-Myc-CAT) are shown in Figure I. In the transient expression assay (CAT 
assay) for these plasmids, the CAT activity for E2F mutant plasmid decreased about 8.5-fold, 
comparing with that for the wild type plasmid, when superinfected with HSV-1. These results 
strongly suggested that E2F played an important role in transactivation of human c-myc gene 
expression by HSV-1 immediate-early proteins. This is in accord with the early observation that 
E2F plays an important role in the regulation of c-myc gene expression (34, 69). 
4. SCOPE OF THIS THESIS 
Early observations described above showed that (i) cellular regulatory protein YY 1, in 
conjunction with HSV-1 immediate-early proteins, might activate the HSV-1 major capsid protein 
7 
:1 
!i 
VP5 promoter (4); (ii) YYl is an activator for the c-myc gene expression (57); (iii) there is a 
potential YYl binding site located at the downstream from the P2. Early studies also revealed that~ 
in certain cases, regulatory elements located downstream from the promoter might be involved in 
affecting the promoter activity. Huang et al reported that the VP5 leader (the sequence at 
downstream from the VPS promoter) is required for full-level expression by means of the series 
deletion and transient expression assay (CAT assay) (35). Another report made by Guzowski et al 
also demonstrated that the downstream activation sequence (DAS), a 14 hp element located at 
between +22 and +33 (from the transcriptional start site) in the 5'untranslated leader region of the 
UL38 gene, was required for the full level of transcriptional activity of the UL38 (late gene) 
promoter (28). All these data led to the hypothesis that the region at the downstream from P2 in 
the c-myc exon 1 may be also important for the HSV-1 immediate-early protein-mediated c-myc 
regulation. 
To test this hypothesis, the region in c-myc exon 1 downstream of the P2 was examined. First, 
the wild type (-10 l/+513-c-myc-CAT) and mutated plasmids (-10 l/+ 212-Llexon 1-c-myc-CA T and 
-101/+332-Llexon 1-c-myc-CAT) were constructed by following ways: (i) The c-myc sequences 
upstream of -101 (relative to Pl), in the c-myc-CAT plasmids (in which the c-myc exon 1 was 
fused to the bacterial chloramphenicol acctyltransferase gene, CAT, were cut out by endonuclease 
digestion. (ii) The desired DNA fragments were isolated and ligated by DNA T4 ligation to 
generate -1011+_513-c-myc-CAT and -101/+212-Llexon 1-c-myc-CAT. (iii) The sequences from 
+ 332 to +513 were cut out by endonuclease digestion of wild type c-myc plasmid -10 l/+513-c-
myc-CAT. Then the desired large DNA fragment was ligated by using DNA T4 ligase, to generate 
-101/+332-Llexon 1-c-myc-CAT. Second, the regulatory roles of c-myc sequences downstream the 
P2 in exon 1 were assayed by HSV-1 superinfection, transfection of wild type or mutated c-myc-
CA T plasmids, and cotransfection of the plasmids containing HSV-1 immediate-early proteins 
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gene. Third, DNA probes were prepared, and el~ctrophoretic mobility shift assay (EMSA) or 
competition EMSA were performed to investigate the possibility that cellular proteins may be 
involved in this regulation. The results. from these experiments suggested that DNA sequences 
located downstream from the P2 were important for regulation of c-myc gene expression by HSV-1 
immediate-early proteins. In this regulation, ICP4 and !CPO appear to function as activators and 
ICP27 as an inhibitor of gene expression. These results, combined with the data from early studies 
in both Dr.Millette's and other laboratories, suggest that the regulation c-myc gene by HSV-1 
immediate-early proteins is mediated through cellular regulatory protein(s) which interact(s) with a 
cis-regulatory elements loeated downstream from the P2 start site within exon 1. 
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MATERIALS AND METHODS 
1. PLASMID CONSTRUCTION (DELETION) 
(A) Construction and subcloning of plasmids -101/+212-~exon 1-c-myc-CAT ahd 
-10 l/+513-c-myc-CA T. 
(1) STRATEGY OF CONSTRUCTION 
The plasmids -2.3-~exon 1-c-myc-CAT and -1.3-c-myc-CAT, kindly provided as· a gift from 
Nissim Hay of the Ben May Institute in Chicago, contain the upstream c-myc promoter element 
from the P 1 transcription start site followed by an undeleted exon 1 or a deleted exon I linked to a 
reporter gene called chloramphenicol acetyltransferase (CAT). The plasmid maps and subcloning 
steps are diagrammed in Figure 2. Two µg of each of these two plasmids was digested by 
endonucleases Sma I and Cla I (7 units of each) in a final buffer concentration of IX KGB [100 
mM potassium glutamate, 25 mM Tris-acetate (pH 7.5), 10 mM magnesium acetate, 50 µg/ul 
bovine serum albumin Fraction V (Sigma), 1 mM f3-mercaptoethanol] (61). The larger fragments 
from these two plasmids were isolated by the DEAE paper electroelution method which has been 
described previously (13). Briefly, the gel was cut at the site that was 3-4 mm in front of the DNA 
band, observed under the UV light following ethidium bromide staining. A piece of Whatman 
DEAE 81 paper that was slightly wider than the DNA band was inserted into the gel at the site that 
was just in front of the DNA band. The DNAs were electroeluted onto the DEAE 81 paper by 
running the gel at 200 volts for about 20 minutes. The DEAE paper containing the plasmid DNAs 
was transferred into a 1 cc syringe which was previously plugged by small amount glasswool. Tut; 
DNAs on the DEAE paper were washed three times using 200 µI each time with solution A [0.1 IV. 
NaCl, 0.1 mM EDTA, and 10 mM Tris-HCI (pH 8.0)] by centrifugation each time at 1600 rpm foc 
30 seconds. Then the DNAs were eluted three times using 120 µI for each time with solution B [l 
M NaCl, 0.1 mM EDTA, and 10 mM Tris-HCI (pH 8.0)]. Finally, the DNAs were recovered by 
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means of ethanol precipitation, and dissolved in lX TE [10 mM Tris-HCI (pH 8. 
EDTA]. 
In order to generate a blunt end at the Cla I site, 200 ng of each two larger fra ents was 
treated with 1 unit of Klenow fragment in a final buffer .concentration of l .5X KG in a total 
volume of 15 µl (61). Following incubation for 30 minutes at RT, the four deoxyrib nucleotides 
were removed by centrifugation through a 0.9 ml Sephadex G-50 spun column (s un column 
chromatography). The column prepared in a 1 ml syringe was equilibrated with TE buffer [ 10 
mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0), 100 mM NaCl], and it was prepared according to 
a procedure described previously ( 61). After the deoxynucleotides were removed, e fragments 
were recovered by ethanol precipitation. Finally about 100 ng of each fragment, wi blunted end 
at both ends, was ligated by incubation with 0.5 unit of T4 DNA ligase in IX T 
buffer [50 mM Tris-HCI (pH 7.6), 10 mM MgC12, 1 mM ATP, 1 mM DJ, 5% (w/v) 
polyethylene·glycol-8000]-in a total volume of 20 µI incubated at l6°C for 24 hours. 
was to generate the new subclones, -101/+513-c-myc-CAT and -101/+212-8exon J-c-myc-CAT, 
containing full-length or a· deletion in exon 1. In generating these two subclones, the , 
Cla I site were removed. 
(2) TRANSFORMATION 
Competent DM 1 cells, a strain of E.coli that lacks the EcoR I and Ava II m thylases, were 
purchased from GIBCO BRL. The competent cells were transformed with the newly ligatec 
plasmids by the method provided by GIBCO BRL. According to this protocol, the transformatior. 
was carried out as follows: For each plasmid, 50 µI DM 1 cells and 3 ng of plas id DNA wer~ 
mixed into a 1.5 ml microfuge tube and incubated on ice for 30 minutes. The mixt res were give-i 
a heat-shock at 37°C (water bath) for 20 seconds, and were put on ice again for tw 
the mixture were transferred into a clean 15 ml polypropylene tube, and 0. 95 ll terrific brotl 
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[1.2% bacto tryptone, 2.4% bacto yeast extract and 0.4% (v/v) glycerol] was added_ Then the 
transformed cells were incubated at 37°C by rotation. Finally, several dilutions of the transformed 
cells were plated onto LB plates (I 00 µl of the undiluted culture, 100 µI of a 10 times diluted 
culture, and 100 µl of a 100 times diluted culture) and incubated at 37°C for 16 to 20 hours. 
(3) DNA EXTRACTION---- MINI AND MAXI PLASMID PREPARATION 
Mini plasmid preparation. The amplified plasmid DNAs (-10 l/+513-c-myc-CAT and -
I 0 II+ 212-.6.exon 1-c-myc-CA T were first extracted by a mini plasmid preparation method termed 
the "TENS" method. Briefly, 1.5 ml of overnight culture, grown in the medium of LB containing 
ampicillin (50 µg/ml), was by sedimented centrifugation at high speed (about 10,ooq rpm) at 4°C 
in a Hermie microcentrifuge. Most of supernatant was poured off (leaving 50 to 100 µI). The 
transformed cells were lysed by adding 300 µl TENS solution [10 mM Tris-HCI (pH 7.5), 1 mM 
EDTA, 0.4% NaOH, and 0.5% (w/v) SDS]. Then the lysed cells were neutralized by adding 150 
µI 3 M sodium acetate (pH 5.2). · The neutralized mixture was centrifuged in Hermie 
microcentrifuge at high speed (about 10,000 rpm) for 2 minutes at 4°C. The supernatant 
containing the plasmid DNAs was transferred into a 1.5 ml microfuge tube. The plasmid DNAs 
were precipitated by adding 0.9 ml 100% ethanol, cooling the mixture to less than. -75°C in the 
Revco -80°C freezer for 20 minutes, and the centrifugation in Hermie microcentrifug~ at high speed 
(about 10,000 rpm) for 5 minutes at 4°C. The supernatant was removed, and the DNA pellet was 
washed with 500 µl 70% ethanol. Finally, the plasmid DNAs were dissolved in 3:~ µl of IX TE 
[10 mM Tris-HCI (pH 8.0), 0.1 mM EDTA] containing 1 unit of RNase A, and the correcr 
subclones were identified by restriction analysis and analytical agarose gel electrophoresis (s~ 
below). 
Maxi plasmid preparation. All materials including resin columns (Qiagen-tip 500) and 
solutions were purchased from the Qiagen, Inc. Plasmid DNAs from large culture (500 ml) we::-e 
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extracted by the Qiagen maxi plasmid preparation method according to the procedures described in 
the Qiagen plasmid handbook which was provided by Qiagen, Inc. Briefly, 500 ml "Terrific 
Broth" [1.2% bacto tryptone, 2.4% bacto yeast extract and 0.4% (v/v) glycerpll medium 
containing ampicillin (50 ng/ml) were inoculated with 5 ml of overnight culture of the ~ransformed 
E coli cells (DM 1 or HBlOl). These cells were grown with vigorous shaking (280 
When they had reached an absorbency of 1 at 600 run (for lower copy plasmids), chl ramphenicol 
(170 µg/ml) was added to amplify plasmid DNAs and the culture was further incub ted at 37°C 
with vigorous shaking (280 rpm) for 12 to 16 hours. The cells were sedimented in a 250 ml 
bottle) by centrifugation at 6,000 rpm at 4°C for 15 minutes and they were resuspendfi with 10 ml 
of Pl solution [100 mM µg/ml RNase A, 50 mM Tris/HCl, 10 mM EDTA (pH 8.~]. Then the 
cells were lysed by mixing with 10 ml of P2 solution (200 mM NaOH, 1% SDS). A 
minutes on ice, the lysate was neutralized by adding I 0 ml of P3 solution [3. 0 M 
Cellular debris and E coli genomic DNA were removed by the centrifugation i 
centrifuge at 13000 rpm at 4°C for 30 minutes. -Plasmid DNAs were separated fro 
RNAs by passing the supernatant solution through a resin column called Qiagen 
DNAs were eluted from the column by adding 15 ml of QF buffer (1.25 mM 
.c (pH 5.5)]. 
Tris/HCl, 15% ethanol,). The eluted DNAs were precipitated with isopropant (see Qiagen 
plasmid handbook for detail). Finally, the extracted DNAs were dissolved in 400 t 500 µI of IX 
TE and they were analyzed by restriction analysis and agarose gel electrophoresis. The correc1 
subcloned plasmids were kept at 4°C. The concentration and total yields of ext 
were measured by calculating their absorbency at 260 run, 280 run, and 320 nm · 
DU-40 spectrophotometer. 
(4) SELECTING SUBCLONES BY RESTRICTION ANALYSIS 
The enzymes used in the restriction analysis were purchased from GIBCO / BRL and Ne-:v 
England Biolabs. The extracted subcloned DNAs from both mini and maxi plasJud preparatioas 
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were checked by the restriction analysis. Briefly, the plasmid DNAs were cleaved wifr_ restriction 
enzymes (endonucleases) so that the circular plasmid DNAs were cut into one linear f::-agment, or 
two or three linear fragments. They were also incubated with enzymes which were not able to 
cleave this specific kind of the plasmid DNA (e.g. in the subcloned plasmids -101/+513-c-myc-
CAT and -101/+212-~exon 1-c-myc-CAT, the Sma I and Cla I sites were removed, so Sma I and 
Cla I were not able to cleave these two plasmids). These fragments, as well as the uncut plasmid, 
were electrophoresed in an agarose gel (gel concentrations depended on the sizes of the fragments) 
using 0.5X TBE (0.54% Tris base, 0.28% boric acid, l· mM EDTA) as the gel ruming buffer. 
DNA fragments with the known sizes, e.g. A/Hind III, were used as size markers in the same gel 
(when the bacteriphage A. digested by endonuclease Hind III, several known size DNA fragments, 
such as 23.1 kbp, 9.4 kbp, 6.68 kbp, 4.36 kbp, 2.3 kbp, 2.1 kbp, and 0.56 kbp, were generated). 
After electrophoresis, the gel was stained by ethidium bromide (0.5 µg/ml) for about 16 minutes, 
and photpgraphed with the Polaroid. film No.667 under the transmitted UV light using a UV 
transilluminator. The .distances of the marker fragments run in the agarose gel were measured, and 
a standard curve, which represented the relationship between fragments sizes and distances, was 
plotted on semi-log paper according to the sizes and distances of the marker fragments. The sizes 
of the sample fragments were determined by measuring the distances of the sample fragments run 
in the gel, and then pointing the distances values on the standard curve. 
(B) Subcloning for plasmid -101/+332-L\exon 1-c-myc-CAT. 
The plasmid map and subcloning steps are diagrammed in Figure 3. Two µg of the plasmid -
101/+513-c-myc-CAT was digested with the endonucleases Hind III and Xho I (eac:n of 7 units) ir 
a final buffer concentration of IX KGB in a total volume of 30 µl for 3.5 hours at 37°C. The: 
larger fragment, the Hind III-Xho I fragment which would be used as the vector, was isolated b; 
the electroelution onto a dialysis membrane (dialysis membrane method) (45). Briefly, a slo"', 
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which was slightly wider than the width of the band (DNA fragment being isolated), wa:; made just 
3 to 4 mm in front of the band in the etbidium bromide stained agarose gel. The Hind III-Xho I 
fragment was run onto a piece of nitrocellulose dialysis membrane (whether the DNAs were 
completely run onto the membrane need to be checked under the UV light) in a l % agarose gel at 
200 volts for about 20 minutes. The fragment was removed from the dialysis membrane by 
running the gel at 200 volts for about 1.4 minutes in the direction opposite to the original gel 
running direction. The DNAs in the slots were collected by pipetting them into a 1.5 ml microfuge 
tube and recovered by ethanol precipitation. Then 100 µg of the plasmid -10 l/+513-~exon 1-c-
myc-CAT were digested again with the endonucleases Hind III and Xho I (each of 350 units) in a 
final buffer concentration of IX KGB in a total volume of 550 µl for 4 hours at 37°C. The smaller 
fragment, the 487 bp Xho I-Hind III fragment (from the Xho I site to Hind III site) was isolated by 
the dialysis membrane method as described above. This fragment (about 2.5 µg) was further 
digested by endonuclease of Ava II (10 units) in a final buffer concentration of lX KGB in a total 
volume of 30 µI for 3.5 hours at 37°C to generate three fragments: a 266 bp Xho I-Ava II 
fragment, a 151 bp Ava II-Ava II fragment, and a 71 bp Ava II-Hind III fragment. All three 
fragments were isolated by means of dialysis membrane method as described above. Then 200 ng 
of the Hind III-Xho I fragment (as a vector) and 30 ng of the 266 bp Xho I-Hind III fragment were 
ligated by using I unit of T4 DNA ligase. In order to generate the blunt ends at the Ava II and 
Hind III sites, the ligated mixture was treated with Kienow fragment as described above. After the 
Kienow fill-in reaction, the deoxynucleotides were removed by passing through a G-50 column as 
described above (61). The new subclone, -101/+332-~exon 1-c-myc-CAT, was generated by 
ligating both blunt ends of the fragment with I unit of T4 DNA ligase incubated at 37C for 24 
hours. In this subcloned plasmid, both the Ava II site and Hind III site were removed. 
The transformation, DNA extraction and restriction analysis processes were the same a: 
described above except that the strain of competent cells used in the transformation was HB 10 I, 
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another strain of E coli, instead of DM 1, and the endonucleases used in restriction analysis (see 
table 4). 
2. DNA PROBE PREPARATION 
Three DNA fragments from c-myc exon 1, the 266bp Xho I-Ava II fragment, the 151bp Ava II-
Ava II fragment, and the 7lbp Ava II-Hind III fragment, were isolated as described above. These 
three fragments were labeled with a.-32P-dA TP and a.-32P-dCTP by means of Kienow fill-in 
reaction (see Fig.4) which was described previously (61). Briefly, each of being labeJed fragment 
was mixed with radioactive deoxynucleotides (labeled with a.-32P-dA TP and a.-32P-dCTP), non-
radioactive deoxynucleotides (dGTP and dTTP), and I unit of Kienow enzyme. The reaction 
mixture was incubated for 20 minutes at room temperature (RT). Then the reaction mixture was 
chased with I mM of each four unlabeled deoxynucleotides for 10 minutes at RT. The Kienow 
fragment activity was inactivated by heating the mixture at 70°C for 10 minutes. The a.-32P-
. labeled or a.-32P-unlabeled deoxynucleotides were removed by passing the reaction mixture through 
a G-50 spun column.. The a.-32P-labeled fragments (probes) were recovered by ethanol 
precipitation and were dissolved in 100 µI IX TE and stored at -20°C. The radioactivities of the 
a.-32P-labeled probes were determined in a Beckman LS6500 liquid scintillation spectrometer. 
3. CELLS AND VIRUS 
Cells and virus used and their propagation were described in the previously publi5hed paper by 
Chen et al (4). Briefly, Hela cells (ATCC CCL2) maintained at 37°C under 5% C02 atmosphere 
in Dulbecco's modified Eagle medium (DMEM~ GIBCO Laboratory Inc.) supplemented with 10% 
(v/v) heat-inactivated fetal bovine serum, penicillin (100 u/ml), and streptomycin (100 u/ml). The 
virus, kindly provided by G.S.Read, Loyola, University of Chicago, was the vsh-1 mutant ofHSV-
1 (KOS) which was defective in the first stage host shutoff function and it was previousl)i 
propagated in HEp-2 cell monolayers by Dr. Millette in the Biology Department of Portland State. 
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University. 
4. TRANSFECTION, COTRANSFECTION AND HSV-1 SUPERINFECTION 
The procedures for ti"ansfection, cotransfection and HSV-1 superinfection were almost same as 
described in the previously published article (24, 25, 50) modified by Chen et al (4), except that in 
the cotransfection assay, the amounts of each plasmid DNA, encoding for HSV-1 immediate-early 
proteins (ICPO, ICP4, ICP27), were 2 µg instead of 8 µg (the plasmid pUC18 was used to adjust 
the total amount of DNAs to 16 µg which represented the total amount of different kinds of 
plasmis in one well). Briefly, Hela cells were seeded in 35-mm well cluster dishes at 3 x 105 cells 
per well in 3 ml DMEM-10% IFBS-P/S (4), and incubated at 37°C in the presence of 5% C02. 
Twenty hours later, the plasmid DNAs were precipitated by a procedure called calcium phosphate-
precipitation. Briefly, for each duplicate, the appropriate mount of plasmid DNAs being 
transfected or cotransfected was.mixed with 0.5 ml of2X HEPES-buffered saline (HES) (280 mM 
NaCl, 10 mM KCI; 1.5 mM Na2HP04, 12 mM dextrose, 50 mM HEPES) in a-5 ml polypropylene 
tube. Then 0.5 ml. of 0.25 M CaCh was added dropwisely with bubbling and the adding of CaCh 
took about 15 seconds. The mixture was incubated at RT for 30 minutes. Then 0.5 ml of calcium 
phosphate-precipitated DNA was transfected (plasmid DNAs containing full length cf c-myc exon 
l or deletions in the c-myc exon I) or cotransfected (plasmid DNAs containing· HSV-1 immediate-
early genes) into Hela cells. Four hours after transfection or cotransfection, the medium was 
removed and the cells were shocked by 1 ml glycerol shock solution (15% (v/v) glycerol in 
DMEM-10% ICFS] for 1 minute. The cells then were washed 2 times with 3 ml PBS-A (0.14 M 
NaCl, 2.7 mM KCl, 4.3 mM Na2HP04, 1.5 mM KH2P04) supplemented with 3 ml DMEM-10% 
IFBS-P/S, and further incubated at 37°C under 5% C02. Twenty hours after the transfection or 
cotransfection, the transfected cells were superinfected with HSV-1 (described in eel~ and virus) a1 
multiplicity of infection of 3. At the meantime, the mediums for the cotransfected cells werf; 
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changed (renewed wi.th the same medium). Both transfected and cotransfected cells were hanrested 
40-44 hours after the transfection or cotransfection. The cells superinfected by HSV-1 were 
checked under the microscope, and were harvested when they were approximately 40-5~% rounded 
even the time was less than 40 hours. The harvested cells were lysed by the method perfomed by 
Nordeen et al (50) Briefly, the cells in each well were rubbed off from well by using a "rubber 
' 
policeman': and were sedimented by centrifugation in a Hermie microcentrifuge at lov'(er speed at 
4°C for 3 minutes. The supernatant was removed by aspiration. Then the cells wrre lysed by 
resuspending them in 100 µl lysis buffer [0.25 M Tris/HCI (pH 7.8), 0.25% (v/v) NP;40, 0.005% 
(w/v) PMSF], mixing them well, and incubating them on ice for 10 minutes. The mixture was 
: 
centrifuged in the Hermie microcentrifuge at lower speed at 4°C for 5 minutes. , Finally the 
supernatant (lysate) was transferred into a clean 1.5 ml microfuge tube, and the lysates were kept 
~ 
at -80°C (in Revco) for CAT assay . 
. 5. CAT ASSAY 
The CAT assay was described previously ( 4, 50), and it consisted of measuring ine;orporation of 
I 
3H-acetate (NEN Research Products, Inc.; 3.3 Ci/mmol, 10 mCi/ml) into acetyl-chl~ramphenicol 
I 
I 
by using a coupled reactiOn with acetyl coenzyme A synthetase (4, 50). Briefly, for each reaction, 
: 
43 µI of distilled water, 31.5 µI of 4X CAB [4X CAT assay buffer (400 mM Tris-HCI pH 7.8, 24 
mM MgCh,and 300 mM KCI)], 3H-labeled acetyl acid (0.78 µCi/µl), IO µI of 5 mM 1Coenzyme A, 
4 µI of 100 mM ATP, and 0.5 µI of 250 mM chloramphenicol were mixed in a 1.5 ml microfuge 
tube and pre-incubated for 30 minutes at 37°C. Then 30 µI of each sample lysate was added to 
each tube and the contents were incubated at 37°C for 2 hours. After the incubatio~, 1 ml of cold 
benzene was added to each reaction tube, and the contents were completely mixe!d by vigorous 
vortexing and inverting. This mixture was centrifuged in Hermie microcentrifuge at high speec 
(about 104 rpm) for 2 minutes at 4°C. After centrifugation, 800 µl solution from the. benzene phase 
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was transferred into a scintillation vial and dried by evaporation. Finally, the radioactivities of 
acetyl chloramphenicol (cpm) was measured in a Beclanan liquid scintillation spectrometer. The 
net cpm of acetyl chloramphenicol for each sample was obtained by subtracting the cpm of the 
control plasmid (e.g. pUC18) which does not contain the CAT gene. 
6. ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA) 
Both HSV-1 uninfected and HSV-1 infected nuclear extracts (NE) were previously prepared by 
Dr.Millette (in Biology Department of PSU) according to the procedures performed by J. D. 
Dignam et al (23). In each reaction, NE containing 2 µg of protein, DNA probe (104 cpm), 1-2 
mM MgCh, and 1 µg polydldCpolydldC (double stranded polydldC) (Pharmacia Biotech) were 
mixed in 0.65 ml microfuge tube. The binding reaction was taken place at RT for 20 tninutes in a 
total volume of 16 µI. Then 1.6 µI of 10% bromophenol blue (BPB) was ad~ed. A 4% 
polyacrylamide gel (PAGE), which was pre-run at 250 volts at 4 °C for about 60 minutes, was used 
for electrophoresis. The running buffer used in this experiment was IX NRB [0.3% (v/v) Tris 
base, 1.43% (w/v) glycine, 10 mM EDTA]. The samples were electrophoresed at 250 volts at 4°C 
for 130 minutes. Then the gel was transferred onto a piece of 3 mm paper, covered with a piece of 
plastic food wrap, and put on a gel slab dryer for 2 hours to dry. The dried gel was covered by a 
RX Fuji film (20.3 x 25.4 cm) which then was exposured for about 13 hours ·at -8CfC. The film 
was developed and analyzed for protein binding. 
7. COMPETITIONEMSA 
Competition EMSAs were run similarly to the EMSA, except that an additional unlabeled 3 3 bp 
dsDNA oligonucleotide, whose sequence is CCAGGATCCAGGGCCA TCTTGAA TGGATCCT-
GG, was added. This oligonucleotide was named LBS (4) was synthesized by Valium Institute, 
Oregon Health Sciences University. It contained a binding site for nuclear protein YY 1, shown in 
the underlined part of the sequence (4, 47). The control probe used in this assay was the 32P-
19 
labeled 160 hp DNA fragment from VP5 (HSV-1 major capsid protein) promoter,- which was 
previously shown to contained the sequence for the cellular protein YY I binding. 
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RESULTS AND CONCLUSIONS 
1. RESULTS 
(1) Preparation and analysis of subclones -101/+513-c-myc-CAT and -101/+212-~exon 
1-c-myc-CAT. 
To determine whether the sequences in the first exon from P2 are important for the activation of 
c-myc gene expression by HSV-1, the plasmids containing deletions in exon 1 of the c-myc gene 
were constructed (see Fig. 2). First, plasmids containing only 101 bp upstream of the c-myc 
promoter were prepared by excising the region from -2.3 kbp to -101 bp in the plasmid -2.3-~exon 
1-c-myc-CAT, and the region from -1.3 to -101 in the plasmid -1.3-c-myc-CAT (both plasmids 
were the gifts from the Nissim Hay in Ben May Institute in Chicago) by digestion with restriction 
endonucleases Sma I and Cla I. The large vector fragment was isolated by the DEAE paper 
electroelution method. The blunt ends were made at the Cla I site of the vector fragments by the 
Kienow fill-in reaction. The two vector fragments were then ligated using T4 DNA ligase to 
generate plasmids -101/+513-c-myc-CAT (used as a wild type control) and -101/+212-~exon 1-c-
myc-CA T. Then the subcloned plasmids were transformed into competent E coli cells,. screened by 
mini plasmid preparation. The correct subcloned plasmid DNAs were extracted by maxi plasmid 
preparation. The total yields from a 500 ml culture was 292 ug for -10 l/+513-c-myc-CA T and 
304 ug for -101/ +212-~exon 1 c-myc-CAT. · 
The resulting plasmids were examined by restriction analysis (see Fig.5 for restriction map). 
First, both -1011+513-c-myc-CAT and -101/+212-~exon 1-c-myc-CAT were digested by 
endonuclease Hind III, Hind Ill/Pvu I, EcoR I, and Sma l/Cla I. The digesting mixtures were run 
in a 1 % mini gel (Fig.10). The mini gel showed that the number of observed bands resulted from 
this digestion is consistence with the number of expected bands (Table 1), and the sizes of observed 
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bands arc approximately estimated to be correct according to the sizes of marker bands I sizes can 
not be accurately measured in mini gel) (Fig.10). To confirm the mini gel results, khese two 
subcloned plasmids were examined in two standard agarose gels, 0. 9% gel for linear I form and 
1.2% gel for diagnostic digestion (most important evidence) by EcoR I and EcoR I/No1 I (Fig.13 
and Table 2). These results indicated that both sizes and numbers of the bands produced coincided 
with those expected from restriction maps. Therefore they appeared to be the correct lsubcloncs. 
To confirm the deletion part of the subclone -101/+212-.6.exon 1-c-myc-CAT, DNA rcquencing 
was carried out. Although part of sequences upstream the Nea I site (+212 hp) could, be read, it 
failed to show the deletion part. Therefore an alternative experiment, the restriction 
small fragment [from Not I site (+22) to Hind III site] spanning the deletion part, wasjperformed. 
Thus the Not I-Hind III fragment (see Fig.5) was isolated and further analyzed the 4igcstion of 
endonucleases Pvu II, Alu I, Xho I, Hinf I, Ava I and Ava II. This analysis showf d that this 
fragment was able to be digested by Xho I only, and it could not be digested by Pvu 11,/Alu I, Hinf 
I, Ava I and Ava II (Fig.11). This result was consistent with the data shown on the Rlasmid map 
(see Fig.5), from Nissim Hay in Ben May Institute in Chicago (32), and confirmeli that the -
10 II+ 212-.6.exon 1-c-myc-CAT was the correct subclone. 
(2) Preparation and analysis of subclone -101/+332-.6.exon 1-c-myc-CAT 
To further determine the more specific region within the c-myc exon 1 which was re ponsible for 
HSV-1 immedi3:te-early proteins mediated human c-myc regulation, the region from 332 to +513 
(181 hp), and the adjacent 40 hp up to Hind III site in the plasmid -101/+513-c-m c-CAT was 
removed by the endonucleases Ava II and Hind III as described above. The subclon -101/+332-
.6.exon 1-c-myc-CAT was generated by first ligating the vector with the 266 hp o I- Ava II 
fragment by T4 DNA ligase (see Fig. 3), treating Kienow fragment to make both ends blunt, finally 
ligating both blunt ends together with T4 DNA ligase. 
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The plasmid DNAs of this subclone were prepared by the Qiagen maxi plasmid preparation 
method (as described above). The total yield from a 500 ml culture was 360 ug. As with the other 
subclones, this subclone was examined by restriction analysis with the endonucleases Hind III, 
EcoR I, Not I, and Xho I (see Fig.5 for the restriction map) first in a 1 % mini agarose gel (Fig.12). 
The mini gel results showed that the number of observed bands is consistence with the number of 
expected bands (Table 1). In Fig.12, it also showed that the sizes of the bands are approximately 
measured to be correct according to the sizes of marker bands (the accurate size can not be 
measured in mini gel). To confirme the mini gel results, this plasmid was examined in two 
different concentration standard agarose gel, 0.9% for· linear form and 1.2% for diagnostic 
restriction (most important evidence). The standard gel is shown in (Fig.10 and 13) and the si~es 
of bands in standard gel were measured (Table 2). The results (shown in Table 1, Table 2, Fig. IO, 
Fig.12, and Fig.13) indicate that both sizes and numbers of the bands agree with those predicted 
from the restriction map. Therefore -10 l/+ 332-D.exon 1-c-myc-CAT subclone is correct. 
(3) Sequences located at downstream from the P2 in the c-myc exon 1 contain the 
responding elements for the ICP4 and ICPO mediated activation 
To determine whether there is a element located downstream from the start site in the c-myc 
gene, P2, which is activated by HSV-1 immediate-early proteins, the subcloned plasmids -
101/+513-c-myc-CAT (as wild type control containing -101 to +513 of c-myc) and -101/+212-
D.exon 1-c-myc-CAT (containing -101 to +212 of the c-myc) were assayed separately two times in 
a transient expression assay system (CAT assay). The linear maps are shown in Figure 5. To test 
their abilities to be transactivated by HSV-1, the HeLa cells were transfected with .each of these 
plasmids, and 20 hours later they were superinfected with HSV-1 at a multiplicity of 3. Parallel 
control cultures remained HSV-1 unsuperinfected. Twenty to twenty four hours after 
superinfection the cells were harvested and their lysates were analyzed for CAT enzyme activity. 
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The results are shown in the Figure 6 and the Table 3. These results showed that the CAf activity 
increased 5. 7-fold for the wild type c-myc plasmid -10 l/+513-c-myc-CA T when HJV-1 was 
superinfected. Similarly, a 3.9-fold and a 1.9-fold increase were observed in the mutant (deletion 
in the first exon of c-myc) c-myc plasmids -101/+212-6exon 1-c-myc-CAT and -101/+ 
1-c-myc-CAT, respectively. Furthermore, when the CAT activity was compared to that 
type - I 011+5 I 3-c-myc-CA T in the presence of HSV-I superinfection, a 5. 2-fold and la 6 .2-fold 
reduction was observed in the cells transfected with the mutant c-myc plasmids -101/+212-6cxon 
1-c-myc-CAT and -101/+332-6exon 1-c-myc-CAT, respectively. When compared to th 
level set at 100%, the represented relative CAT level of 19.2% and 16.1 to the -101/ 212 and -
101/+332 deletion respectively (Fig.6, Table 3). These results were accord with the pr vious data 
from Dr. Millette's laboratory that c-myc gene expression was strongly activated by HSV-1 
infection, and t:hey indicated that the sequences within the first exon of c-myc gene ar1 
for activation by HSV-1 infection. 
According to previous results from this laboratory ( 46), the major activation is 
HSV-1 immediate-early proteins ICP4 and ICPO. To investigate the involvement of 
the +332 to +513 bp region in this activation, the activity of the subclone -101/+33 
myc-CA T was compared with that of the wild-type promoter in two separate cotransfe 
One reason to speculate the region from + 332 to +513 of the first exon of c-myc is i 
the ICP4 and IGPO mediated activation is that it contains a potential binding site fo 
regulatory protein YY I at about +4 5 3 bp. This cellular regulatory protein was previojsly shown to 
be involved in activating the murine c-myc promoter (57) and the HSV-1 VP5 pro 
investigate this, HeLa cells were transfected with wild type and exon I dele~ions oJc-myc-CAT, 
and simultaneously cotransfected with piasmids expressmg HSV-1 IE protems 1t cinta1ns. The 
results of the cotransfection assays (see Fig.7 and Table 4) demonstrate that, comp 
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non-cotransfected cells (transfected with -10 l/+513-c-myc-CAT only), the CAT activatics of the 
wild type c-myc plasmid -101/+513-c-myc-CAT increased 13.7-fold when cotransfectcd with 
ICP4, 16.7-fold when cotransfected with ICP4 and ICPO, and it was reduced 1.5-fold when 
cotransfected with ICP4, ICPO, and ICP27. Relative to the wt (-101/+513) set at 100%, 
cotransfection of ICP4 alone was 78.3%, and ICP4, 0, and 27 was 5%. On the other hand, the 
similar comparison in the c-myc mutated plasmid showed that the CAT activity of the plasmid -
101/+332-~exon 1-c-myc-CAT increased 2.1-fold when cotransfected with ICP4, a1d 4.5-fold 
when cotransfected with ICPO, and it was reduced 1.1-fold when cotransfected with all three HSV-
1 immediate-early proteins. Relative to the wt CAT plasmid induced with ICP4/ICPO (as I 00%), 
this deleted plasmid (-101/+332) gave the CAT level of 2.5%, 16.0%, and 0.9% when 
cotransfected with ICP4, ICP4/ICpO, and ICP4/ICPO/ICP27, respectively. These results lead to 
two suggestions: (i) The region from +332 to +513 contains an element required for c-myc gene 
activation by HSV-1 immediate-early proteins. (ii) ICP4+ICPO together provid~ maximum 
transactivation, ICP4 appears to provide the major, single transacting effect, and ICP27 functions 
to inhibit its expression. 
( 4) Are there any binding sites for cellular regulatory proteins in the region from + 3 3 2 to 
+513 in the first exon of c-myc gene? 
To determine whether any cellular regulatory protein(s) bind(s) to the c-myc exon I reg10n 
between +66 and +513 hp, electrophoretic mobility shift assays were carried out with three c-myc 
fragments spanning this region. These fragments were 266 hp Xho I-Ava II fragment [from +66 
hp to +332 hp (see Fig. 5)], 151 hp Ava II-Ava II fragment [from +332 hp to +483 hp (see Fig. 
5)], and 71 hp Ava II-Hind III fragment [from +487 hp to +513 hp, and up to Hind III site at the 
start site of the CAT gene (see Fig. 5)]. Because of the data derived from CAT assay, we 
emphasized examining the region from +332 to +513 in the c-myc exon I. The results of the: 
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EMSA (Fig.8) showed: (i) There are two major shift bands observed in the lanes for t e 266 hp 
Xho I-Ava II probe (Fig.8, lane 11 and 12). (ii) There were three shifted bands (two m jor bands 
and one minor band) observed both for the 151 hp Ava II-Ava II probe which contains potential 
binding site for transcription factor YYl (Fig.8, lane 6 and 7), and 71 hp Ava II-Hin III probe 
(lane 2 and 3). Previous studies have shown that HeLa cell nuclear extracts form 2 
YY 1, one representing a YY I degradation product ( 4). Therefore two of these bands could be 
caused by YY 1. To determine if any of these bands were formed by YY 1, the competitikm EMSAs 
were carried out. The results showed (Fig.8): (i) Positive control probe (VP5) has two 
caused by YYI binding. They appear to be lowered in intensity when the LBS is preseµt. (ii) The 
bands observed in the 266 bp probe are only slightly competed. (iii) The intensity of khese bands 
did not diminished when the radioactive 151 hp Ava II-Ava II probe was competed wit1a290- and 
400-fold molar excess of LBS, a unlabeled 33 bp dsDNA fragment containing a YYI binding site 
(Fig.8, lane 8 and 9). This indicated that these shifted bands were not due to the ii binding. 
(iiii) Three bands (two major bands and one minor band) were observed when 71 b 
used. The two major shifted bands disappeared when competed with a 400-fold molar excess of 
LBS, indicating that these bands were due to binding of the cellular regulatory protein,/YYI (Fig.8, 
lane 4). This observation was confirmed by early data from competition EMSAs usirk 32P-labeled 
222 bp Ava II-Hind III fragment (from the Ava II site at +332 within c-myc exon l to 
and see Fig.5 for map). In this experiment, C2, a dsDNA fragment not containing 1 binding 
site, was used as a negative control oligonucleotide. The results showed that t1e two bands 
supposed to be caused by YYI binding diminished when the 222 bp Ava II-Hind II probe was 
competed with LBS, but they did not diminished when the probe was competed wi 
Thus, the possibility that the two bands were caused by non-specific proteins 
excluded. However, from the sequence analysis, there was no YYl consensus bin 
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found in this region , indicating that YY I was not a factor involved in HSV-1 immediate-early 
proteins mediated regulation of human c-myc gene. This looks like somewhat contradictory. 
There are two possible explanations: (i) the 40 bp vector sequence (see Fig.5) constructed by Hay 
contains a YYI binding site; (ii) the region from +483 to +513 might contain a non-consensus or 
high degenerated YYI binding site. According to the second explanation, the role of the cellular 
protein YYI in the HSV-1 immediate-early proteins mediated c-myc regulation still could not 
excluded. 
2. CONCLUSION 
The results from these studies lead to the follow conclusions: 
( 1) HSV-1 immediate-early proteins are regulators for human c-myc gene expression in transient 
assays. ICP4 is the major transactivator, ICPO is a minor transactivator, and ICP27 s~rves as an 
inhibitor of the c-myc gene expression. 
(2) The region from +332 to +513 in the exon I of the c-myc gene contains a seque:oce which is 
responsible for the ICP4 and !CPO mediated transactivation of human c-myc gene expression 
[other important regions upstream of the P2, such as E2F site, were also identified in previous 
studies (46)]. 
(3). The data from my EMSA ·results suggest that at least one cellular regulatory protein is 
involved in viral regulation of the human c-myc gene through sequences in exon 1. 
(4). From the data derived from the EMSA and competition EMSA, I conclude that the cellular 
regulatory protein YYl is not likely involved in the HSV-1 mediated regulation of human c-myc 
gene through the exon 1 sequences. However, there is a possibility that a non-consensus YYl 
binding site may be involved for the regulation by this region of the c-myc gene. 
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DISCUSSION . 
Early studies revealed that c-myc expression is regulated, either positively or negatively, , by 
many factors at different stages (e.g. it may be regulated at level of initiation of transctiption or at 
level of elongation of transcription). Many target sequences for cellular transcription factors have 
been identified in the c-myc promoter in the region between 2.3 kbp and the transcfription start 
sites, Pl and P2 (10, 33). Recently Dr. Millette and J. Paulson found that HSV-1 i~ediate-early 
proteins (mainly ICP4) could activate the expression of c-myc gene (46). Their s· 
showed that this activation was related to a target sequence for cellular protein E2F bPiding. This 
binding site was located between P 1 and P2 (around + 117) ( 46). Consistant with the results shown 
by Millette and Paulson, the experiments presented here also demonstrate that the 
gene is regulated by the HSV-1 immediate-early proteins. In these experiments, adclitional target 
sequences for HSV-1 immediate .. early proteins (ICP4 and ICPO) mediated activation i~ identified in 
the region downstream from P2 (between +332 and +513 hp), within the first exonjof the c-myc 
gene. The exact mechanism involved in this regulation was not established. 
We have already shown that three immediate-early proteins, ICP4 ICPO, and ICPl7 play a role 
in regulating both viral and cellular genes. All three of the HSV-1 immediate-early proteins are 
nuclear phosphoproteins that are able to regulate the expression of other genes. ICPj4 is the major 
transcriptional activator of HSV-1, although it represses its own expression (6, ll, 26). It has 
been reported to bind DNA nonspecificically (21 ), but it also binds to some of its $get sites in a 
sequence-specific pattern. Its high affinity binding sites have been identified! as A TCGT -
CNNNNYGRC (where R is purine, Y is pyrimidine, N is any base (20, 44), and all of its binding 
sites conform to the consensus sequence RTCGTCNNYNYSG (where R is pur!e, Y is pyri-
midine, Sis C or G, and N is any base) (11). Early studies showed that the activa on function o:· 
ICP4 is independent on the specific binding. Imbalzano suggested that ICP4 m~y activate the 
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·expression of HSV-1 early and late genes by a mechanism that does not require sequence-specific 
binding (36). Similar to this suggestion, other laboratories demonstrated that the mutations in 
either the ICP4 target sequence or in the ICP4 binding domain did not affect its transactivation 
function (64, 65). 
Early studies and my data showed: (i) ICP4 binding concensus binding sites were not found in 
the region from +332 bp to +513 bp within the exon 1 (J. Paulson, personal communication), and 
the binding ofICP4 to its target sequence might not be required for its activation function. (ii) The 
data derived from transient expression (CAT assay) showed that the region from +332 bp to +513 
hp in the first exon of c-myc was important for the regulation of c-myc gene expression by HSV-1 
infection. (iii) The data from EMSA and competition EMSA demonstrated that some cellular 
proteins bound to the DNA sequences in the region from +332 bp to +513 bp. (iiii) The early data 
from this laboratory (46) and the data in this paper showed that the ICP27 inhibition of c-myc 
expression seemed mainly to inhibit the ICP4 mediated transactivation. Early studies also revealed 
that ICP27 was involved in the secondary host shutoff process. Taken together these observations, 
it is reasonable to· speculate that cellular factor(s) is/are involved in the ICP4 mediated activation 
of human c-myc gene expression at the level of transcription. This speculation may also be 
supported by the early studies that human c-myc expression depends on the presence of cellular 
proteins. However, the previous studies, described above (40, 71, 72), might also give rise to the 
possibility that ICP4 might bind to a site which was of the low affinity or high degeneracy type= 
and the human c-myc gene expression might be activated by this binding. Therefore the possibili~ 
that ICP4 directly transactivates human c-myc gene expression still can not be excluded. 
In contrast, among these three immediate-early proteins, ICPO is the only one that activates al 
three kinetic classes (ex., p, y) ofHSV genes, without apparent DNA sequence specificity (17, I~, 
49, 51, 54). It is able to further enhance the expression of any gene that exhibits a basal level cf 
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transcription (71). There are many reports which showed that ICPO exhibits j synergistic 
transactivation with ICP4 (71, 72), and our cotransfection assay results are concord t with these 
reports. This synergistic transactivation may require the physical interaction betwedn ICPO and 
ICP4 (71). ,Recent study also revealed that ICP4 appeared to be required for I the nuclear 
localization of ICPO (72) 
ICP27 is another HSV-1 immediate-early protein involved in the regulation otj c-myc gene 
expression. Although early showed that ICP27 alone was able to inhibit the expresJon of c-myc 
gene, early data (46) and my experiments demonstrated that ICP27 mainly inhibited I 
c-myc activation. Previous study revealed that ICP27 is involved in the secondary s~ge shutoff of 
the host proteins synthesis (31). When cells were infected with HSV-1 mutants defJctive ICP27, 
the shutoff host protein synthesis was greatly reduced.(59). Other studies showedl that ICP27 
regulated cellular genes expressions post-transcriptionally (31, 62, 67), and that retlation (both 
activation and repression) was not dependent on the target gene promoters, but on th ir processing 
signals (62). For the inhibitory activity of ICP27, the presence of intrans in the target genes were 
required. (62). These observations suggest that the inhibitory function ofICP27 we ve observed 
in the regulation of human c-myc gene might also occur at the post-transcriptional 1 vel. If this is 
true, it is reasonable to consider the possibility that the mechanism of ICP27 -repre sion of c-myc: 
gene expression might be due to inhibition of action of certain cellular proteins. 
activated by ICP4, possibly and/or ICPO might be required for activating human 
ese proteins,. 
binding to the region from +332 to +51_3 within exon I. These possibilities support ~e speculatior 
that cellular regulatory factor(s) is/are involved HSV-1 mediated regulation of hurr)an c-myc gem= 
expression. ICP27 can also inhibit the nuclear localization of ICPO (72), and redluce the ICP4-
ICPO synergy. This would therefore inhibit the ICP4-ICPO synergistic activation. 
In summary, my experiments demonstrate that the HSV-1 immediate-early 
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ICP4, ICP27 are the regulators of the human c-myc gene. The results of cotransfection experiment 
showed that the relative CAT activity observed for wild type c-myc plasmid is 1 E% for non-
cotransfection, 78.3% for the cotransfection of ICP4 alone, 100% for the cotra...,sfection of 
ICP4/ICPO, and 5% for the cotransfection of ICP4/ICPO/ICP27. The relative CAT activity for the 
mutated c-myc plasmid -101/+332-8exon 1-c-myc-CAT is 1.7% for non-cotransfection, 2.5% for 
cotransfection of ICP4 alone, 16% for cotransfection ofICP4/ICPO, and 0.9% for cotransfection 
of ICP4/ICPO/ICP27 (the CAT activity observed in wild type c-myc plasmid cotransfected with 
· ICP4/ICPO is set as 100%). Therefore ICP4 is the major transactivator whereas ICP27 inhibits the 
expression of the c-myc gene. This inhibition was observed either at basal level of c-myc 
expression (minor effect) (46) or in the ICP4 mediated c-myc activation (major effect). This 
implied that cellular proteins may be involved, because of its host shutoff function. The 
cotransfection results, together with the HSV-1 superinfection results, also suggest that one of the 
responding element in the c-myc exon l is located at the region from +332 bp to +513 bp 
downstream of the P2. In addition, the results from the EMSA and competition EMSA show that 
some cellular proteins bound to this region (Picture 1). This also implies that cellula1 proteins may 
be involved in this regulation. 
Taken together with the observations from Dr. Millette's previous studies (46) and earlier studies 
on the HSV-1 immediate-early proteins (31, 36, 46, 59, 62, 65), my results suggest that cellular 
regulatory factor(s) may be involved in the ICP4 mediated human c-myc gene activation. 
Hypotheoretically, ICP4 may activates cellular protein(s) which in turn bind(s) to their ta~ge1 
sequences in the c-myc gene and activate(s) c-myc gene expression. The exact mechanism o:· 
HSV-1 immediate-early proteins mediated regulation of c-myc gene is still unclear and it need;. 
further investigation. 
In my opinion, Further study will include DNA footprinting. This experiment will give info .. 
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mation of the exact cellular proteins binding sites. From the data derived from the DNA footprint~ 
these binding sites could be used to compare with the binding sites of known proteiru. Thus the 
possible kinds of proteins bound to the c-myc gene may be obtained. 
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Subclones 
Enzyme 
Number of 
observed 
bands 
Number of 
expected 
bands 
-1O1 /+513-c-Myc-CAT 
Hind I Hind III/ I Sma II 
III Pvu I Cla I 
2 no cut 
2 no cut 
1011+212-~xon 1-c-Mvc-CAT 
Hind I Hind III/ I Sma I/ 
III . Pvu I Cla I 
2 no cut 
2 no cut 
-101/+332-~exon 1-c-Mvc-C.ttT 
Hind III I Xho I I Pst I I Kho II 
bst I 
no cut 12 
no cut :2 
Table 1. Results of restriction analysis in mini-gels for the subclones -101/+513-c-Myc-CAl" -101/+212-
Aexon 1-c-Myc-CAT, and -101/+212-~exon 1-c-Myc-CAT. The results indicate that t number of 
observed bands are consistence with that of the expected bands. See Fig. IO, and Fig.12 for ~gel. 
Subclone 
Enzyme 
Number of 
observed 
bands 
Number of 
expected 
bands 
size of 
observed 
bands 
size of 
expected 
bands 
conclusion 
-101/+513-c-Myc-CAT 
Pst I I EcoR I I EcoR II 
Not I 
1 2 2 
1 2 3 (see •• ) 
-101/+212-~xon 1-c-Mvc-CAT 
Pst I I EcoR I I EcoR II 
Not I 
1 2 2 
1 2 3 (see·°) 
0.94 kbp I 0.80 kbp 
1
6.0 kbp I 0.61 kbp 0.46 kbp 
6.3 kbp l and a lar- • and a large and a lar- and a lar-
size band·. size band". ge size ge size 
band·. band·. 
0.93 kbp 1146 bp;- 6.0 kbp 0.63 kbp 146 bp,--
6.3 kbp I and 0.79kbp, and 0.484 kbp, 
5.37,kbp and 5.37kbp and 
5.37 kbp 5.37 kbp 
all subcloned plasmids are correct 
-101/+332-&xon 1-c-M+c-CAT 
Pst I I EcoR I I I' EcoR l/ 
Not I 
I 
I 
1 2 I 2 
1 2 : 3 (see"") 
0.71 kbp 0.55 kbp 
6.10 kbp and a lar-
1 
and a large 
ge size 
band·. 
size band" 
0.71 kbp '146 hp,"" 
6.08 kbp and '0.564 kbp, 
5.37 kbp and 5.37 
'kbp. 
: 
: 
Table 2. Results of the restriction analysis of the subcloned c-myc plasmids -101/+513 c-Myc-CAT, -
101/+212-L\exon 1-c-Myc-CAT, and -101/+332-L\exon 1-c-Myc-CAT in two different co centrations of 
agarose gel (0.9% and 1.2%) .. The results indicate that both the number and sizes of obs ' ed bands are 
same or very close to those of the expected bands. The most convincing evidence that t ey are correct 
plasmids is derived from the measurement and comparison of the diagnostic bands. The ~ze differences 
in these bands represent the deletion parts in the exon 1. The gels are shown in Fig.IO 0.9% gel) and 
Fig.13 (1.2% gel for the diagnostic digestion by EcoR I and EcoR I/Not I). 
*The sizes of the larger fragments .in Fig.13 can not be measured because of the conc~htration of the: 
agarose gel (1.2%). The larger marker DNA fragments can not be separated welll at the higher 
concentration gel. 1 
··The 146 bp fragment in Fig.13 is too small to be detected. The reason to examine the Ec;QR I/Not I band 
is that this band is really important for the diagnostic purpose. I: 
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Plasmids HSV-1 
-101 /+513-c-myc-CAT 
+ 
-101/+212-Aexon 1-c-myc-CAT 
+ 
-10 l /+513-c-myc-CAT 
+ 
-101/+332-Aexon 1-c-myc-CAT 
+ 
CAT Activity (pmol 3H-
0Ac Chloramphenicol/ 
mg Protein/h 
5.8 x 103 
39.0 x 103 
1.9 x 103 
7.5 x 103 
7.2 x 102 
31.0 x 103 
3.2 x 102 
5.1x102 
percentage of1duced 
CAT activity the wild 
type c-myc pl mid (%) 
14.9 
100.0 
4.9 
19.2 
23.2 
100.0 
10.3 
16.1 
Table 3. Relative CAT activities for the the wild type and mutated c-myc plasmids -101/+f 13-c-myc-
CAT, -101/+212Aexon 1-c-myc-CAT, and -101/+332-Aexon 1-c-myc-CAT in two separ te HSV-1 
superinfections. The CAT activity represents pmol chloramphenicol acetylated/mg protein/h. The CAT 
activity of wild type -101/+513-c-myc-CAT superinfected by HSV-1 is set as 100%. 
Transfected plasmid I Cotransfected I pmol 3H OAC Chloram- I percentage o induced 
plasmid phenicoUmg Protein/h CAT activity f the wild 
smid % 
ICP4 9.4Xl0 78.3 
-1 Ol/+513-c-Myc-CAT ICP4/ICPO l.2Xl04 100.0 
ICP4/ICPO/ICP27 6.0X102 5.C 
ICP4 3.0XIO 2.: 
-101/+332-~exon 1-c-Myc-CAT ICP4/ICPO 2.0XlO 16.( 
ICP4/ICPO/ICP27 l.1X102 o.o 
Table 4. Relative CAT activities for the the wild type and mutated c-myc plasmids -101/£513-c-Myc-
CAT and -101/+332-Aexon 1-c-myc- CAT in two separate cotransfection experiments. The AT activity 
represents pmol chloramphenicol acetylated/mg protein/h. The CAT activity of wild type 101 /+513-c-
myc-CAT cotransfected with ICP4/ICPO is set as 100%. 
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.CP ' 
. i 
I 
! 
i 
I 
fos/fun 
Octyy1 
1•0 
-353 -240 
pl 
5Sp1 -101 
/ "'-. +1 +66 
p2 
~ 
Exon I 
~52--103' / +t74~ 
· E2F CTI ~ 
+66 wt-Myc-CAT 0-•--11-----E-xo_n_l _ __,I 
+66 +117 +134 +174 
mtE2F 
P2 
+66 mtE2F-Myc-CAT Exon I 
+17.4 +513 
Fig.1. The maps of the wild type plasmid of +66-c-myc-CAT and the E2F-site mutat<fd plasmid, 
c-myc+66 mtE2F-CAT. 
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-1.3 
-2.3-aexon 1-~Myc-CA T 
CAT 
-101/+212-Aexon 1-c-Myc-CAT 
-1.3-c-Myc-CA T 
- .... -..:+174 
c-Myc 
.xon I 
513 
Hind Ill 
-101/+513-c-Myc-CAT 
Fig.2 Map and steps in constructing wild type plasmids -101/+513-c-myc-CAT and 
-101/+212-Liexon 1-c-myc-CAT. The vector plasmid is pBR322. 
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+66 
Hindlll-Xhol 
frngment 
:T4 ligase 
+174 
.---r--
CAT 
+66 
~ 
Xhol 
40bp 
CAT 
t513 
• 3;2 ·r3 ( Hindlll 
Avail Avnll 
·· Avall 
483 +513 
+66 +332 +3~ + ~ndll 
X;:.; p Avall Avall Avall 
Avail C 
[266bp] [151bp] 71bp] 
(These three fragments are also labeled by 
hot 32P-dATP and 32P..dCTP and are used ns 
DNA probes in EMSA) 
klenow +4 dNTP 
then T 4 ligase 
CAT 
P2 
-101/+332-Aexon 1-c-Myc- CA-
Fig.3 Map and steps in constructing the subcloned plasmid -101/+332-~exon 1-c-myc -CAT. The vectoc 
plasmid is pBR322. The fragments used as probes in electrophoretic mobility shift assay (EMSA) and h 
competition EMSA are also shown. 
37 
Xho I-Ava II fragment Ava II-Ava II fragment Ava 11-Ht-d Ill fr agm•nt 
ITCGi b ~ 1cAGI ~ II 
I I 
kLEN~] 
a-nP-dATP 
a!
2
P-dCTP 
dGTP 
dTTP 
'( ~· 
laA~1 
* = ~ ~ AGCT CAG * * * 
Fig.4. Diagram of the DNA probes prepared. *represents cx.-32P-labeled deoxynucldotides. 
All three probes were labeled by Kienow fill-in method. 
c-Myc exon 1 
B~mHI 
P~t I PYu I EcoR I Not I Xho I P2 ltll'ld Ill 
NnlAh1I Av~R Av~U Pw~I . 
·101 P1 downstr•am rom t • 
1--~~-------------tt----~~~-., P2 of the- c-M c ~ 
Piii• 626bp .. IL 
-10 l /+51 '3-c-Myc-CAT 
P~t I pyql 
23bp 
EcoRI 
·101 
.. 111• 626bp ... IL 
-101/+212-A-exon 1-c-Myc-CAT 
23bp 
P~tl Pyql 
•1•22 •66 
NotlXhol 
P1. . 
+1•22•66 
•174 I •242 •332 •483 •513 14111i1l-- 255bp 
•212 
40bp 
from Nu I site (•212) to 
Pvu II site ( ·513) is cl4!'1ete-d 
N~~I 
P2 
•174•212 
Nc~IAl11I 
P2. 
40bp ' 
from Ava II site (•332) to 
Hind m site is dele-ted 
EcoRI 
EcoRI 
EcoRI EcoRI 
·101 
Diii.. 626bp llto IL 
NotlXt.ol 
P1. . 
•1•22 •66 
lf$~;~~1t:i ~~~-· ~'.'i{::1 
-101/+332-A-exon 1-c-Myc-CAT 
23bp 
•114 1 ·242 
•212 
~255b~-4'-1 
Fig.5. The restriction maps of the three subcloned c-myc plasmids, -101/+513-c-my~-CAT, 
-101/+212-Aexon 1-c-myc-CAT, and -101/+332-Aexon 1-c-myc-CAT. The deleted 
parts of the two deletion mutated c-myc plasmids are also shown in this figurt;. 
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AGCT 
-101 /+513-c-Myc-CAT 
-101 /+212-A-exonl-c-Myc-CAT 
r-i 
-101/+332-A-exonl-c-Myc-CAT -
10 20 30 40 50 60 70 80 90 100 
percentage of relative CAT cativity (9Q 
Fig.6. The relative CAT activities (use the CAT activity of the wild-type c-myc plasmid super-
infected with HSV-1as100%) of the three subclones, -101/+513-c-myc-CAT, -101/-212-
~exon 1-c-myc-CAT, and -101/+332-~exon 1-c-myc-CAT in two separate HSV-1 infections. 
The CAT activity of 100% represents pmol chroramphenicol acetylated/mg protein/h. 
-1011·513-c-M!lc-CAT ~none ................ · · · · · · .11CP4 ICP411CPO -~·.·.······:.-:.··~~········· .. 
none 
;ICP4 -1011•332-A.eson 1-c-M!lc-CAT $ ICP411CPO 
ICP411CP811CP27 
10 20 30 40 50 60 70 80 90 100 
percentage of relative CAT cativity (%) 
Fig.7. The relative CAT activities in two separate cotransfection assays (use wild type ::-myc 
plasmid cotransfected with ICPO/lCP4 as 100%) for subclones -101/+513-c-myc-CAT 
and -101/+332-~exon 1-c-myc-CA T. The CAT activity of 100% represents pmol chro-
ramphenicol acetylated/mg protein/h. 
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DNA probes 71 bp 151 bp 266 bp VPS 
LBS (fold, molar excess) 400 200 400 200 400 300 
NE (HSV infected, µg) 2 4 4 2 4 4 4 2 4 4 4 4 4 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
........ -- ' -, .... 
•••• 
' '_, 
/·~/~ 
<. l'J., ~. 
i 
' 
+.-YYla 
- . 1, ) . 
I 
·- ·_ _- . -- -- . 
Fig.8. Results of the electrophoretic mobility shift assay (EMSA) and competition EMSA. The probes 
used in this experiment are 71 bp Ava II-Hind III fragment, 151 bp Ava II-Ava II fragment, and 266 bp 
Xho I-Ava II fragment, and a 164 bp fragment from VP5 promoter is used as the positive control. A non-
radiolabled oligonucleotide (LBS) containing YYl binding site is used to compete with radiolabled 
probes. All probes are bound with proteins in the EMSA, but only 71 bp probe is competed with LBS 
(lane 4). P represents free probe. 
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DNA probes 
C2 (fold, molar excess) 
LBS (fold, molar excess) 
NE (HSV uninfected, µg) 2 
1 2 3 
.... ~ ... "' ., .... ,,. .,._ 
I' 
iJ'. 
222 bp 
150 
2 
4 5 
VPS 
400 
300 
2 2 2 
6 7 8 9 10 11 
~YYla 
~YYlb 
~p 
Fig.9. Result of the competition electrophoretic mobility shift assay using unlabeled oligonucleotide C2 as 
a negative control. The probe used in this experiment is a 222 bp Ava II-Hind III fragment, spanning 
from the Ava II site at +332 to the Hind III site (see Fig.5). The result shows that the binding of protein 
(YYl) to this probe is competed by unlabeled oligonucleotide LBS, but it is not competed by unlabeled 
oligonucleotide C2 (See lane 2, 4, 6, 8,). P represents the free probe. VP5 probe is used as a control. 
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A. B. 
123 A.45 6 A. 1 2 3 4 5 6 7 8 9 10 11 12 13 
Fig.10 . Two separate agarose gels for the restriction analysis of the wild type c-myc plasmid -101/+513-
c-myc-CAT and mutated c-myc plasmid -101/+212-L'l.exon 1-c-myc-CAT. (A) Pst I digestion to generate 
linear form of these two subclones (lane 4 for wild type c-myc plasmid -10 l/+513-c-myc-CA T and lane 5 
for mutated c-myc plasmid -101/+212-L'l.exon 1-c-myc-CAT). Lane 3 is the Pst I digestion of -101/+212-
L'l.exon 1-c-myc-CAT (the size is shown in Table 4). The gel concentration is 0.9% and the running buffer 
is 0.5X TBE. (B) The digestion of these two subclones by different endonuclease enzymes (lanes 2 to 7 
for -101/+212-ti.exon 1-c-myc-CAT and lanes 8 to 13 for -101/+513-c-myc-CAT. Lanes 3 and 9 show the 
linearization of these two plasmids by the Hind III digestion. Lanes 4, 5, 6, 10, 11 , and 12 show the Pvu 
I/Hind III and EcoR I digestion to produce two bands. Lanes 7 and 13 show that the endonucleases Sma I 
and Cla I can not digest these two subclones. The gel concentration is I% and the running buffer is 0.5X 
TBE. 
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123456 
Fig.11 . The Not I-Hind III fragment is analyzed by the endonucleases Xho I, Pvu II, Alu I,Ava II, and 
Hinf I. The gel concentration is 4% and the running buffer is 0.5X TBE. The undigested '.'Jot I-Hind III 
fragment (the size of this fragment was previously proven to be correct) is used as size marker. The 
picture shows that this fragment is only digested by Xho I to generate a 40 bp smaller fragm~nt (lane 2) . 
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1 2 3 4 5 'A 6 7 'A 8 9 10 11 12 13 
Fig.12 . Photograph of the mini agarose gel for the restriction analysis of the subclone -1 01/+332-~exon 
1-c-myc-CAT. The gel concentration is 1% and the running buffer is 0.5X TBE. Lane l is the uncut 
control. Lane 2 shows that this subclone can not be digested by Hind III . Lanes 3, 4, 6, and 8 show the 
linearization of this subclone by Xho I (lane 3), Pst I (lane 4), Hind IIl/Xho I (lane 6) and Hind III/Pst l. 
Lane 5 shows that the Xho l/Pst I digestion generates two bands (size shown in Table 4). Lane 10 shows 
the two bands generated by Xho I/Pst I digestion. Lane 12 is the digestion by EcoR I (clearer photo is 
shown in Fig.3). Lanes 5, 9, 11 , and 13 are the digestion of wild-type c-myc plasmid by Hind III (lane 5) , 
Hind III/Pst I (lane 9), Xho l/Pst I (lane 11), and EcoR I (lane 13). 
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A.123 A.45 6 
Fig.13. Photograph of the agarose gel for the diagnostic restriction analysis of the subclo:ied plasmids -
101/+513-c-myc-CAT, IOI/+212-6exon 1-c-myc-CAT, IOI/+332-6exon 1-c-myc-CAT. The gel concen-
tration is 1.2% and the running buffer is 0 .5X TBE. Lanes I , 2, and 3 show the EcoR I di&estion of these 
three plasmids. Lanes 4, 5, and 6 show the EcoR I/Not I digestion of these three plasmids. 
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